Biotechnology

Incyte

Insightec pays $120 million to expand collaboration with Genesis Molecular AI

Insightec Partners with Edison Science to Deploy Kosmos AI Platform for Accelerated Drug Development

Sette Medical Announces Positive Results of Tafasi Tamab Combined with Lenalidomide and R-CHOP Trial

Incyte Conducts Clinical Trial for INCB161734 in Pancreatic Cancer Treatment

Sette Medical Announces Opzelura Cream Phase 3 Trial Data and Plans to Submit CTA

Insitute Medical's NIKTIMVO Receives Priority Review Approval from Australia's TGA

Incyte Announces FDA Approval of Jakafi XR for Treating Three Conditions

Incyte Raises Jakafi Full-Year Guidance with Strong 2025 Q2 Earnings

Incyte released FY2026 Q1 earnings on April 28 Pre-Market (EST), actual revenue USD 1.273 B (forecast USD 1.211 B), actual EPS USD 1.47 (forecast USD 1.012)

FDA Criticizes Incyte's Misleading Promotion of Niktm vo

INCY's MINJUVI® Receives Approval in Australia for Follicular Lymphoma

Insulet CEO Sells $1.8 Million in Company Stock

Incyte Highlights Phase 3 Data for Tafasitamab at ASCO Annual Meeting

Incyte to Release FY2026 Q1 Earnings on April 28 Pre-Market EST, Forecast Revenue USD 1.226 B, EPS USD 1.0212

Insitec Medical's IBD SmartSelect Composite Rating Rises to 96

Incyte and Adagene Collaborate to Study Muzastotug and INCA33890

Adagene Announces Strong Muzastotug Data and Partnership with InCyte for MSI-Colorectal Cancer

Incyte's Experimental Drug Povorcitinib Shows Positive Results in Late-stage Trial for HS

Incyte to Present Povorcitinib Efficacy and Safety Data at 2026 American Academy of Dermatology Annual Meeting

Incyte Outlines Sustainable Growth Strategy at Barclays Conference

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

GCL Global

Jupiter Neurosciences

Linkage Global

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Capstone

HCW Biologics

Pinned News

置顶新闻

Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront

INCY

LABU

ARKG

Incyte has expanded its collaboration with Genesis Molecular AI, paying USD 120 million upfront, which includes USD 80 million in cash and USD 40 million in equity. The partnership aims to broaden the use of the GEMS platform across more targets, with potential milestone payments exceeding USD 1 billion. Incyte retains exclusive rights to develop and commercialize products from this collaboration.

PUBT

VanEck Biotech ETF

iShares US Pharma

Health Care Select Sector SPDR

SPDR S&P Biotech

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

iShares Biotechnology ETF

LABD

Incyte Stock: Analyst Estimates & Ratings

Barchart Option

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VG Health

Proshares Ultra Nasdaq Biotech

Incyte Stock: Analyst Estimates & Ratings

Incyte CEO Bill Meury highlighted the company's clearer post-Jakafi growth path, driven by ongoing commercial growth and late-stage pipeline developments. He noted Jakafi's continued sales growth and the potential of new products like Jakafi XR and OPZELURA. Meury emphasized the core business's expected growth, projecting it to reach $3-$4 billion without aggressive assumptions, and discussed upcoming product launches and market expansions.

Market Beat

Bank of America

Argenx

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte Corp. (INCY) shares fell 2.38% to $95.31 on Friday, marking the fourth consecutive day of losses. The stock is 15.12% below its 52-week high of $112.29. In comparison, competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin also experienced declines. The overall market was down, with the S&P 500 and Dow Jones falling 1.24% and 1.07%, respectively.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Factset Research

Incyte Corp. Stock Underperforms Friday When Compared To Competitors

Incyte Corp. (INCY) shares fell 1.20% to $97.63 on Thursday, marking the third consecutive day of losses, despite a positive trading session for the overall market. The S&P 500 rose 0.77%, while Incyte's stock is now 13.06% below its 52-week high of $112.29. Competitors like Alnylam Pharmaceuticals saw a rise of 0.68%, while Bio-Techne and BioMarin experienced slight declines. Trading volume was below the 50-day average.

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

Incyte Corp. (INCY) shares fell 1.19% to $99.13 on Tuesday, ending a two-day winning streak, while the Dow Jones rose 0.11% and the S&P 500 fell 0.16%. The stock is 11.72% below its 52-week high of $112.29. In comparison, competitors like Alnylam Pharmaceuticals (ALNY) rose 2.52%, while Bio-Techne (TECH) remained unchanged and BioMarin Pharmaceutical (BMRN) increased by 0.57%. Trading volume was 1.6 million, surpassing the 50-day average of 1.5 million.

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

PRLD

Prelude Therapeutics Inc reported Q1 2026 revenue of $4.58M, a significant increase from $0.0 in Q1 2025, driven by an upfront payment from Incyte. The net loss narrowed to $(10.4) M from $(32.1) M YoY, with diluted EPS improving to $(0.13). The company initiated a Phase 1 trial for PRT12396 and executed a $100M exclusive option agreement with Incyte, with potential milestones of up to $775M. Prelude also raised approximately $90M in equity to support operations for the next year.

TradingView

Prelude Therapeutics

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress | INCY Stock News

StockTitan

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress | INCY Stock News

Incyte Corp. (INCY) shares rose 1.79% to $100.32 on a strong trading day, outperforming competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin, which saw declines. The S&P 500 and Dow Jones both increased by 0.19%. Incyte's stock is currently 10.66% below its 52-week high of $112.29 reached on January 7th, with trading volume at 1.7 million, surpassing its 50-day average of 1.5 million.

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Incyte(INCY.US)

Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront

Incyte Stock: Analyst Estimates & Ratings

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte Corp. Stock Underperforms Friday When Compared To Competitors

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress | INCY Stock News

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Trending